Cytotoxicity of diacetoxyscirpenol is associated with apoptosis by activation of caspase-8 and interruption of cell cycle progression by down-regulation of cdk4 and cyclin B1 in human Jurkat T cells

Toxicol Appl Pharmacol. 2007 Jul 15;222(2):190-201. doi: 10.1016/j.taap.2007.04.011. Epub 2007 May 8.

Abstract

To understand the mechanism underlying T-cell toxicity of diacetoxyscirpenol (DAS) from Fusarium sambucinum, its apoptogenic as well as growth retardation activity was investigated in human Jurkat T cells. Exposure to DAS (0.01-0.15 microM) caused apoptotic DNA fragmentation along with caspase-8 activation, Bid cleavage, mitochondrial cytochrome c release, activation of caspase-9 and caspase-3, and PARP degradation, without any alteration in the levels of Fas or FasL. Under these conditions, necrosis was not accompanied. The cytotoxicity of DAS was not blocked by the anti-Fas neutralizing antibody ZB-4. Although the DAS-induced apoptotic events were completely prevented by overexpression of Bcl-xL, the cells overexpressing Bcl-xL were unable to divide in the presence of DAS, resulting from the failure of cell cycle progression possibly due to down-regulation in the protein levels of cdk4 and cyclin B1. The DAS-mediated apoptosis and activation of caspase-8, -9, and -3 were abrogated by either pan-caspase inhibitor (z-VAD-fmk) or caspase-8 inhibitor (z-IETD-fmk). While the DAS-mediated apoptosis and activation of caspase-9 and caspase-3 were slightly suppressed by the mitochondrial permeability transition pore inhibitor (CsA), both caspase-8 activation and Bid cleavage were not affected by CsA. The activated normal peripheral T cells possessed a similar susceptibility to the cytotoxicity of DAS. These results demonstrate that the T-cell toxicity of DAS is attributable to not only apoptosis initiated by caspase-8 activation and subsequent mitochondrion-dependent or -independent activation of caspase cascades, which can be regulated by Bcl-xL, but also interruption of cell cycle progression caused by down-regulation of cdk4 and cyclin B1 proteins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Chloromethyl Ketones / pharmacology
  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects*
  • Caspase 8 / metabolism*
  • Caspase Inhibitors
  • Cell Cycle / drug effects*
  • Cell Cycle Proteins / metabolism
  • Cell Survival / drug effects
  • Cyclin B / metabolism*
  • Cyclin B1
  • Cyclin-Dependent Kinase 4 / metabolism*
  • Cyclosporine / pharmacology
  • Cysteine Proteinase Inhibitors / pharmacology
  • Cytochromes c / drug effects
  • Cytochromes c / metabolism
  • DNA Fragmentation / drug effects
  • Dose-Response Relationship, Drug
  • Down-Regulation / drug effects
  • Enzyme Activation / drug effects
  • Humans
  • Jurkat Cells
  • Mitochondria / drug effects
  • Mitochondria / enzymology
  • Mitochondria / metabolism
  • Mitochondrial Membrane Transport Proteins / metabolism
  • Mitochondrial Permeability Transition Pore
  • Oligopeptides / pharmacology
  • Phytohemagglutinins / pharmacology
  • T-Lymphocytes / drug effects
  • T-Lymphocytes / metabolism
  • T-Lymphocytes / pathology
  • Trichothecenes / pharmacology*
  • bcl-X Protein / metabolism

Substances

  • Amino Acid Chloromethyl Ketones
  • Antineoplastic Agents
  • CCNB1 protein, human
  • Caspase Inhibitors
  • Cell Cycle Proteins
  • Cyclin B
  • Cyclin B1
  • Cysteine Proteinase Inhibitors
  • Mitochondrial Membrane Transport Proteins
  • Mitochondrial Permeability Transition Pore
  • Oligopeptides
  • Phytohemagglutinins
  • Trichothecenes
  • bcl-X Protein
  • benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone
  • benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone
  • Cyclosporine
  • Cytochromes c
  • Cyclin-Dependent Kinase 4
  • Caspase 8
  • diacetoxyscirpenol